CoChat

Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Weight loss in patients with type 2 diabetes can improve glycemic control, lower blood pressure, and improve dyslipidemia. Glucagon-like peptide (GLP-1) receptor agonists are associated with weight loss and have potentially beneficial effects on cardiovascular risk biomarkers; however, there is limited information to indicate whether these effects remain outside of clinical trials. RESEARCH DESIGN AND METHODS: Medical records from the General Electric Centricity research database were analyzed retrospectively to evaluate the relationship between weight loss and glycemic control and changes in blood pressure and lipids in patients with type 2 diabetes initiating therapy with exenatide, sitagliptin, or insulin. Baseline and follow-up (90–365 days after the index date) for weight, A1C, fasting blood glucose (FBG), blood pressure, triglycerides, and LDL, HDL, and total cholesterol were assessed. RESULTS: A total of 6,280, 5,861, and 32,398 patients receiving exenatide, sitagliptin, or insulin, respectively, were included in the analysis. Exenatide-treated patients lost a mean ± SD of 3.0 ± 7.33 kg, sitagliptin-treated patients lost 1.1 ± 5.39 kg, and insulin-treated patients gained 0.6 ± 9.49 kg. There was a significant association between weight loss and a reduction in A1C and FBG with exenatide only and a reduction in blood pressure for all therapies. Weight loss was associated with some improvements in lipids, primarily in the GLP-1 receptor agonist group, with little association in the insulin group. CONCLUSIONS: Weight reduction with GLP-1 receptor agonists was associated with a shift toward a more favorable cardiovascular risk profile. Outcome trials are needed to determine whether improvement in biomarkers translates into a reduction in cardiovascular events in patients with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-2062

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Odds ratio and 95% CI of the association of weight loss (percentage from baseline) with any reduction in (A) A1C, (B) FBG, (C) SBP, (D) DBP, (E) triglycerides, (F) total cholesterol, or (G) LDL cholesterol and (H) increases in HDL cholesterol relative to no weight loss after adjustment for covariates.*P < 0.05, **P < 0.0001, compared with patients who did not lose weight. Orange, exenatide; green, sitagliptin; red, insulin.
Figure 1 Odds ratio and 95% CI of the association of weight loss (percentage from baseline) with any reduction in (A) A1C, (B) FBG, (C) SBP, (D) DBP, (E) triglycerides, (F) total cholesterol, or (G) LDL cholesterol and (H) increases in HDL cholesterol relative to no weight loss after adjustment for covariates.*P < 0.05, **P < 0.0001, compared with patients who did not lose weight. Orange, exenatide; green, sitagliptin; red, insulin.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Bergenstal, 2009, Exenatide once weekly improved cardiometabolic risk factors in subjects with type 2 diabetes during one year of treatment, Diabetes, 58, A165

Cited by

Items 101–156 of 156

Metadata

Authors
Horton, E. S., Silberman, C., Davis, K. L., & Berria, R.
Affiliations
  • Joslin Diabetes Center (US)
  • Roche Laboratories, Nutley, New Jersey; and
  • RTI Health Solutions (US)
Corresponding author
Horton, Edward S.
Venue
Diabetes Care
Published
2010-05-11
Volume
33
Issue
8
Pages
1759-1765
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2099903872
Cited by
156
References
23
Citations by year
2026: 2 · 2025: 5 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 2 · 2017: 14 · 2016: 9 · 2015: 13 · 2014: 16 · 2013: 15 · 2012: 21
FWCI
14.28
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
type 2 diabetes, weight loss, glycemic control, GLP-1 receptor agonists, exenatide, sitagliptin, insulin therapy, cardiovascular risk markers, blood pressure, dyslipidemia, HbA1c, fasting blood glucose, lipid profile
MeSH terms
Sitagliptin Phosphate, Exenatide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides, Pyrazines, Triazoles, Venoms, Cohort Studies, Weight Loss, Multivariate Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.